{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T02:23:56Z","timestamp":1767666236897},"reference-count":22,"publisher":"Harborside Press, LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2]]},"abstract":"Background:<\/jats:bold> Most safety and efficacy trials of the SARS-CoV-2 vaccines excluded patients with cancer, yet these patients are more likely than healthy individuals to contract SARS-CoV-2 and more likely to become seriously ill after infection. Our objective was to record short-term adverse reactions to the COVID-19 vaccine in patients with cancer, to compare the magnitude and duration of these reactions with those of patients without cancer, and to determine whether adverse reactions are related to active cancer therapy. Patients and Methods:<\/jats:bold> A prospective, single-institution observational study was performed at an NCI-designated Comprehensive Cancer Center. All study participants received 2 doses of the Pfizer BNT162b2 vaccine separated by approximately 3 weeks. A report of adverse reactions to dose 1 of the vaccine was completed upon return to the clinic for dose 2. Participants completed an identical survey either online or by telephone 2 weeks after the second vaccine dose. Results:<\/jats:bold> The cohort of 1,753 patients included 67.5% who had a history of cancer and 12.0% who were receiving active cancer treatment. Local pain at the injection site was the most frequently reported symptom for all respondents and did not distinguish patients with cancer from those without cancer after either dose 1 (39.3% vs 43.9%; P<\/jats:italic>=.07) or dose 2 (42.5% vs 40.3%; P<\/jats:italic>=.45). Among patients with cancer, those receiving active treatment were less likely to report pain at the injection site after dose 1 compared with those not receiving active treatment (30.0% vs 41.4%; P<\/jats:italic>=.002). The onset and duration of adverse events was otherwise unrelated to active cancer treatment. Conclusions:<\/jats:bold> When patients with cancer were compared with those without cancer, few differences in reported adverse events were noted. Active cancer treatment had little impact on adverse event profiles.<\/jats:p>","DOI":"10.6004\/jnccn.2021.7113","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T20:23:55Z","timestamp":1644265435000},"page":"160-166","source":"Crossref","is-referenced-by-count":21,"title":["Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine"],"prefix":"10.6004","volume":"20","author":[{"given":"Rebecca M.","family":"Shulman","sequence":"first","affiliation":[{"name":"1Department of Radiation Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Weinberg","sequence":"additional","affiliation":[{"name":"2Department of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A.","family":"Ross","sequence":"additional","affiliation":[{"name":"3Department of Biostatistics,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Ruth","sequence":"additional","affiliation":[{"name":"3Department of Biostatistics,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn F.","family":"Rall","sequence":"additional","affiliation":[{"name":"4Institute of Cancer Research, Blood Cell Development and Function,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Olszanski","sequence":"additional","affiliation":[{"name":"5Department of Hematology\/Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Helstrom","sequence":"additional","affiliation":[{"name":"6Department of Surgical Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Hall","sequence":"additional","affiliation":[{"name":"7Department of Clinical Genetics, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Judd","sequence":"additional","affiliation":[{"name":"5Department of Hematology\/Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Y.T.","family":"Chen","sequence":"additional","affiliation":[{"name":"6Department of Surgical Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert G.","family":"Uzzo","sequence":"additional","affiliation":[{"name":"6Department of Surgical Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy P.","family":"Dougherty","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riley","family":"Williams","sequence":"additional","affiliation":[{"name":"4Institute of Cancer Research, Blood Cell Development and Function,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Geynisman","sequence":"additional","affiliation":[{"name":"5Department of Hematology\/Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn Y.","family":"Fang","sequence":"additional","affiliation":[{"name":"8Institute of Cancer Research, Cancer Prevention and Control, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard I.","family":"Fisher","sequence":"additional","affiliation":[{"name":"5Department of Hematology\/Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marshall","family":"Strother","sequence":"additional","affiliation":[{"name":"6Department of Surgical Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Huelsmann","sequence":"additional","affiliation":[{"name":"5Department of Hematology\/Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Adige","sequence":"additional","affiliation":[{"name":"5Department of Hematology\/Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter D.","family":"Whooley","sequence":"additional","affiliation":[{"name":"5Department of Hematology\/Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Zarrabi","sequence":"additional","affiliation":[{"name":"5Department of Hematology\/Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brinda","family":"Gupta","sequence":"additional","affiliation":[{"name":"5Department of Hematology\/Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pritish","family":"Iyer","sequence":"additional","affiliation":[{"name":"5Department of Hematology\/Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"McShane","sequence":"additional","affiliation":[{"name":"5Department of Hematology\/Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilario","family":"Yankey","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles T.","family":"Lee","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Burbure","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren E.","family":"Laderman","sequence":"additional","affiliation":[{"name":"9Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Giurintano","sequence":"additional","affiliation":[{"name":"9Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Reiss","sequence":"additional","affiliation":[{"name":"9Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric M.","family":"Horwitz","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","reference":[{"key":"ref201","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/GO.20.00097","article-title":"COVID-19 and cancer: lessons from a pooled meta-analysis","volume":"6","author":"Desai","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ejca.2021.05.006","article-title":"The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: early data from a single-institute survey","volume":"153","author":"Di Noia","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-021-01046-w","article-title":"COVID-19 vaccines for patients with cancer: benefits likely outweigh risks","volume":"14","author":"Hwang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1158\/2159-8290.CD-20-1817","article-title":"Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discov"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41416-020-01219-3","article-title":"COVID-19 vaccine race: watch your step for cancer patients","volume":"124","author":"Fanciullino","year":"2021","journal-title":"Br J Cancer"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(21)00155-8","article-title":"Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors","volume":"22","author":"Waissengrin","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41416-020-01219-3","article-title":"COVID-19 vaccine race: watch your step for cancer patients","volume":"124","author":"Fanciullino","year":"2021","journal-title":"Br J Cancer"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejca.2021.05.007","article-title":"Adherence to COVID-19 vaccines in cancer patients: promote it and make it happen!","volume":"153","author":"Curigliano","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ejca.2021.05.006","article-title":"The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: early data from a single-institute survey","volume":"153","author":"Di Noia","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(21)00155-8","article-title":"Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors","volume":"22","author":"Waissengrin","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11912-020-00934-7","article-title":"COVID-19 and cancer: a comprehensive review","volume":"22","author":"Gosain","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejca.2021.05.007","article-title":"Adherence to COVID-19 vaccines in cancer patients: promote it and make it happen!","volume":"153","author":"Curigliano","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/GO.20.00097","article-title":"COVID-19 and cancer: lessons from a pooled meta-analysis","volume":"6","author":"Desai","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-021-01046-w","article-title":"COVID-19 vaccines for patients with cancer: benefits likely outweigh risks","volume":"14","author":"Hwang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11912-020-00934-7","article-title":"COVID-19 and cancer: a comprehensive review","volume":"22","author":"Gosain","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1158\/2159-8290.CD-20-1817","article-title":"Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discov"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/2\/article-p160.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/20\/2\/article-p160.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T18:33:40Z","timestamp":1644604420000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/2\/article-p160.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":22,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2021.7113","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}